Itolizumab as the First Line of Treatment in Moderate to Severe Chronic Plaque Psoriasis- A Case Report
Abstract
Abstract
Psoriasis is a chronic, autoimmune disease with a genetic predisposition. Among the various therapeutic options, biological therapies are emerging as a novel therapy in the management of this disease. Here, we present a case report of a patient who received Itolizumab as the first line of therapy.
Keywords: Psoriasis, Biologic, Itolizumab
Downloads
Download data is not yet available.
Published
01-03-2016
How to Cite
Trasi, S. S., and N. Sashidharan. “Itolizumab As the First Line of Treatment in Moderate to Severe Chronic Plaque Psoriasis- A Case Report”. Asian Journal of Pharmaceutical and Clinical Research, vol. 9, no. 2, Mar. 2016, p. 12, https://journals.innovareacademics.in/index.php/ajpcr/article/view/10418.
Issue
Section
Case Study(s)
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.